Professor Man Li: From Uncertainty to Definitive Evidence—PostMONARCH Study Proves the Benefit of Cross-Line Treatment with CDK4/6 Inhibitors| Man Talks Breast Cancer: ASCO Special
In this "Man Talks Breast Cancer: ASCO Special," Professor Man Li's team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in premenopausal women. These can provide more valuable insights for clinical practice.